Cancer immunotherapy setbacks with CAR T cell therapy
A promising fresh cancer treatment is facing a deadly setback
Cancer cells seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, in 2012. Reuters
- Cancer immunotherapy, or treatments that use the figure’s immune system, have been gaining traction in the past few years.
- That’s especially true with a group of therapies called “checkpoint inhibitors.”
- But there have been some setbacks to other approaches, including cell therapies, with some cases turning deadly.